The pathology of hepatic iron overload

Iron Physiology and Pathophysiology in Humans

Volumn , Issue , 2012, Pages 345-355

  Deugnier, Yves ^a   Turlin, Bruno ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cirrhosis; Ferritin; Fibrosis; Hemosiderin; Hepatocellular carcinoma; Iron overload; Liver; Perls' Prussian blue

Indexed keywords

EID: 85028691393     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-485-2_17     Document Type: Chapter

References (66)

1. Feder JN. The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Immunol Res. 1999;20:175-85.
2. Deugnier Y, Brissot P, Loréal O. Iron and the liver: update 2008. J Hepatol. 2008;48:S113-23.
3. Turlin B, Deugnier Y. Evaluation and interpretation of iron in the liver. Sem Diag Pathol. 1998;15:237-45.
4. Turlin B, Loreal O, Moirand R, Brissot P, Deugnier Y, Ramee MP. Histochemical detection of hepatic iron. A comparative study of four Stains. Ann Pathol. 1992;12:371-3.
5. Brissot P, Bourel M, Herry D, et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology. 1981;80:557-65.
6. Imbert-Bismut F, Charlotte F, Turlin B, et al. Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring. J Clin Pathol. 1999;52:430-4.
7. Scheuer P, Williams R, Muir A. Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol. 1962;84:53-64.
8. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16:491-4.
9. Deugnier YM, Loreal O, Turlin B, et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology. 1992;102:2050-9.
10. Deugnier YM, Turlin B, Powell LW, et al. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases. Hepatology. 1993;17:30-4.
11. Turlin B, Deugnier Y. Histological assessment of liver siderosis. J Clin Pathol. 1997;50:971.
12. Deugnier Y, Margules S, Brissot P, et al. Comparative study between biochemical and histological methods and image analysis in liver iron overload. J Clin Pathol. 1982;35:45-51.
13. Olynyk J, Hall P, Sallie R, Reed W, Shilkin K, Mackinnon M. Computerized measurement of iron in liver biopsies: a comparison with biochemical iron measurement. Hepatology. 1990;12:26-30.
14. Olynyk JK, O'Neill R, Britton RS, Bacon BR. Determination of hepatic iron concentration in fresh and paraffi nembedded tissue: diagnostic implications. Gastroenterology. 1994;106:674-7.
15. Deugnier Y, Turlin B, le Quilleuc D, et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am J Surg Pathol. 1997;21:669-75.
16. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology. 1997;112:882-8.
17. Villeneuve JP, Bilodeau M, Lepage R, Cote J, Lefebvre M. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol. 1996;25:172-7.
18. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-62.
19. Pietrangelo A. Non-invasive assessment of hepatic iron overload: are we fi nally there? J Hepatol. 2005;42:153-4.
20. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol. 2000;95:1788-93.
21. Brunt EM. Pathology of hepatic iron overload. Semin Liver Dis. 2005;25:392-401.
22. Fracanzani AL, Fargion S, Romano R, et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology. 1995;22:1127-31.
23. Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fi brosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44:472-7.
24. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fi brosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115:929-36.
25. Beaton M, Guyader D, Deugnier Y, Moirand R, Chakrabarti S, Adams P. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology. 2002;36:673-8.
26. Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fi brosis among U.S. Patients with phenotypic hemochromatosis. Ann Intern Med. 2003;138:627-33.
27. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S79-86.
28. Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Nat Cancer Inst. 1985;75:81-4.
29. Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology. 2001;33:647-51.
30. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-62.
31. Deugnier YM, Guyader D, Crantock L, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology. 1993;104:228-34.
32. Morcos M, Dubois S, Bralet MP, Belghiti J, Degott C, Terris B. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol. 2001;116:738-43.
33. Deugnier YM, Charalambous P, Le Quilleuc D, et al. Preneoplastic signifi cance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology. 1993;18:1363-9.
34. Blanc JF, Bernard PH, Carles J, Le Bail B, Balabaud C, Bioulac-Sage P. Cholangiocarcinoma arising in Von meyenburg complex associated with hepatocellular carcinoma in genetic haemochromatosis. Eur J Gastroenterol Hepatol. 2000;12:233-7.
35. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis. 2004;32:131-8.
36. Rosmorduc O, Wendum D, Arrive L, et al. Phenotypic expression of ferroportin disease in a family with the N144H mutation. Gastroenterol Clin Biol. 2008;32:321-7.
37. Arden KE, Wallace DF, Dixon JL, et al. A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon islands patient. Gut. 2003;52:1215-7.
38. Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals. 2003;16:205-13.
39. Kono S, Suzuki H, Takahashi K, et al. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology. 2006;131:240-5.
40. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood. 2000;96:4071-4.
41. Gordeuk VR. African iron overload. Semin Hematol. 2002;39:263-9.
42. Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med. 1992;326:95-100.
43. Deugnier Y, Loreal O, Carre F, et al. Increased body iron stores in elite road cyclists. Med Sci Sports Exerc. 2002;34:876-80.
44. Jakobovits AW, Morgan MY, Sherlock S. Hepatic siderosis in alcoholics. Dig Dis Sc. 1979;24:305-10.
45. Harrison-Findik DD. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol. 2007;13:4925-30.
46. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fi brosis. Hepatology. 1986;6:24-9.
47. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:68-71.
48. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117:1155-63.
49. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 1997;349:95-7.
50. Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc'h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol. 2001;116:263-70.
51. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol. 2003;30:137-44.
52. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol. 1995;26:1080-5.
53. Boucher E, Bourienne A, Adams P, Turlin B, Brissot P, Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut. 1997;41:115-20.
54. Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 2000;31:730-6.
55. Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007;13:97-104.
56. Hayashi H, Yano M, Fujita Y, Wakusawa S. Compound overload of copper and iron in patients with Wilson's disease. Med Mol Morph. 2006;39:121-6.
57. Alla V, Bonkovsky HL. Iron in nonhemochromatotic liver disorders. Sem Liver Dis. 2005;25:461-72.
58. Cotler SJ, Bronner MP, Press RD, et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol. 1998;29:257-62.
59. Brissot P, Wright TL, Ma WL, Weisiger RA. Effi cient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest. 1985;76:1463-70.
60. Detivaud L, Nemeth E, Boudjema K, et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood. 2005;106:746-8.
61. Kijima H, Sawada T, Tomosugi N, Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer. 2008;8:167.
62. Turlin B, Juguet F, Moirand R, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology. 1995;22:446-50.
63. Ko C, Siddaiah N, Berger J, et al. Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the national hemochromatosis transplant registry. Liver Int. 2007;27:1394-401.
64. Nahon P, Sutton A, Rufat P, et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology. 2008;134:102-10.
65. Bottomley SS. Secondary iron overload disorders. Semin Hematol. 1998;35:77-86.
66. Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol. 2006;4:1403-10.